Nexalis Therapeutics Limited (ASX:NX1)
Australia flag Australia · Delayed Price · Currency is AUD
0.0210
0.00 (0.00%)
At close: Mar 9, 2026

Nexalis Therapeutics Ratios and Metrics

Millions AUD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Market Capitalization
56761115
Upgrade
Market Cap Growth
-3.44%-23.11%35.75%-51.02%-25.89%46.10%
Upgrade
Enterprise Value
6675912
Upgrade
Last Close Price
0.020.020.030.030.060.09
Upgrade
PS Ratio
6.977.4818.594.57453.0683.43
Upgrade
PB Ratio
-4.52-4.89-116.798.275.915.66
Upgrade
P/TBV Ratio
---8.275.955.69
Upgrade
EV/Sales Ratio
7.377.2918.564.21376.7564.44
Upgrade
Debt / Equity Ratio
-0.63-0.63-0.530.84--
Upgrade
Net Debt / Equity Ratio
-0.26-0.262.52-0.23-1.12-1.05
Upgrade
Net Debt / EBITDA Ratio
---0.111.102.53
Upgrade
Net Debt / FCF Ratio
-0.34-0.340.440.081.162.42
Upgrade
Asset Turnover
0.800.800.350.630.010.08
Upgrade
Inventory Turnover
-----11.19
Upgrade
Quick Ratio
0.550.550.831.676.0911.14
Upgrade
Current Ratio
0.590.590.921.736.3211.48
Upgrade
Return on Equity (ROE)
---402.12%-112.39%-84.14%-55.53%
Upgrade
Return on Assets (ROA)
-110.17%-110.17%-69.85%-46.40%-47.07%-28.73%
Upgrade
Return on Capital Employed (ROCE)
197.20%197.20%2010.10%-213.80%-102.70%-41.50%
Upgrade
Earnings Yield
-34.42%-31.84%-16.19%-26.23%-17.15%-7.33%
Upgrade
FCF Yield
--15.46%-4.94%-35.65%-16.43%-7.65%
Upgrade
Buyback Yield / Dilution
-1.06%-1.06%-12.72%-9.42%-3.27%-68.94%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.